« MinervaX announces investment of 4.4 mEUR | Main | Innovation Foundation Grant »
Thursday
Jan052017

MinervaX announces results from Phase I clinical trial

MinervaX announces positive results from Phase I trial in 240 healthy adult women with its innovative Group B Streptococcal (GBS) vaccine to prevent life-threatening infections in newborns.